Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of propranolol for CNS hemangioblastomas in von Hippel-Lindau disease
2022-001174-54Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of propranolol in Haemangioblastoma and von Hippel–Lindau disease (VHL) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Started Apr 2022; status: active.
02
Drugs
propranolol
03
Conditions
Haemangioblastomavon Hippel–Lindau disease (VHL)
Beyond the preview
Go deeper on 2022-001174-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001174-54.